Cyr Financial Inc. Has $844,000 Stock Holdings in Eli Lilly and Company $LLY

Cyr Financial Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 31.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,083 shares of the company’s stock after acquiring an additional 262 shares during the quarter. Cyr Financial Inc.’s holdings in Eli Lilly and Company were worth $844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 0.6% in the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares during the period. Finally, Nuveen LLC bought a new position in Eli Lilly and Company during the 1st quarter worth about $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Finally, Cantor Fitzgerald lowered their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Trading Up 1.4%

Shares of Eli Lilly and Company stock opened at $724.73 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. The firm’s 50-day moving average price is $734.15 and its two-hundred day moving average price is $766.60.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.